BCL2 and neoplasm: By cross-referencing the findings from CTRP and PRISM, we identified six potential candidate compounds: apicidin, a histone deacetylase inhibitor; ABT−737, a Bcl-2 family inhibitor; BMS−754807, a tyrosine kinase inhibitor The inhibitor ouabain and the histone deacetylase (HDAC) inhibitors panobinostat and RITA (Reactivating p53 and Inducing Tumor Apoptosis).